Azienda Ospedaliera di Perugia

The Azienda Ospedaliera di Perugia Neurofisiopatologia unit is investigating targeted treatments for IgA nephropathy, an immune‑mediated kidney disorder. The study evaluates early corticosteroid intervention and novel SGLT2 inhibitor regimens to affect disease progression.

• Assess early corticosteroid therapy based on biopsy findings
• Compare SGLT2 inhibitor (Dapagliflozin) plus RAS blockade versus standard steroid‑RAS approach
• Measure impact on proteinuria and renal function
• Explore personalized treatment strategies for active versus chronic lesions

Findings could influence future care at Azienda Ospedaliera di Perugia by providing safer alternatives to high‑dose steroids.

The Neurofisiopatologia department is conducting a trial on amyotrophic lateral sclerosis, a progressive neuromuscular disease. Researchers are evaluating whether acetyl‑L‑carnitine can slow functional decline and preserve independence.

• Test two dosage levels of acetyl‑L‑carnitine
• Monitor changes in the ALSFRS‑R functional rating scale
• Assess safety and tolerability in ALS patients
• Determine potential to delay loss of self‑sufficiency

Positive outcomes may expand therapeutic options for ALS patients treated at Azienda Ospedaliera di Perugia.